Oppenheimer analyst Steven Lichtman raised the firm’s price target on Boston Scientific to $59 from $58 and keeps a Perform rating on the shares. Boston Scientific’s Q2 sales beat forecasts, and EPS was also ahead of Street expectations, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BSX:
- Boston Scientific raises FY23 adjusted EPS view to $1.96-$2.00 from $1.90-$1.96
- Boston Scientific sees Q3 adjusted EPS 46c-48c, consensus 48c
- Boston Scientific reports Q2 adjusted EPS 53c, consensus 49c
- BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR SECOND QUARTER 2023
- Notable companies reporting before tomorrow’s open